Bank of New York Mellon
AUPH icon

Bank of New York Mellon’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bank of New York Mellon’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.95M Buy
350,857
+15,082
+4% +$241K ﹤0.01% 2340
2026
Q1 		$4.98M Buy
335,775
+6,422
+2% +$93.9K ﹤0.01% 2319
2025
Q4 		$5.25M Buy
329,353
+15,851
+5% +$225K ﹤0.01% 2297
2025
Q3 		$3.46M Sell
313,502
-12,306
-4% -$134K ﹤0.01% 2532
2025
Q2 		$2.76M Sell
325,808
-27,462
-8% -$220K ﹤0.01% 2590
2025
Q1 		$2.84M Sell
353,270
-1,908
-0.5% -$15.5K ﹤0.01% 2507
2024
Q4 		$3.19M Sell
355,178
-5,425
-2% -$44.3K ﹤0.01% 2520
2024
Q3 		$2.64M Sell
360,603
-128,118
-26% -$794K ﹤0.01% 2615
2024
Q2 		$2.79M Buy
488,721
+77,510
+19% +$408K ﹤0.01% 2611
2024
Q1 		$2.06M Buy
411,211
+17,573
+4% +$119K ﹤0.01% 2748
2023
Q4 		$3.54M Sell
393,638
-4,284
-1% -$35.3K ﹤0.01% 2541
2023
Q3 		$3.09M Sell
397,922
-4,512
-1% -$44.1K ﹤0.01% 2562
2023
Q2 		$3.9M Buy
402,434
+3,869
+1% +$40.2K ﹤0.01% 2463
2023
Q1 		$4.37M Sell
398,565
-5,269
-1% -$46.4K ﹤0.01% 2379
2022
Q4 		$1.74M Sell
403,834
-3,517
-0.9% -$20.4K ﹤0.01% 2924
2022
Q3 		$3.06M Buy
407,351
+35,854
+10% +$310K ﹤0.01% 2571
2022
Q2 		$3.73M Buy
+371,497
New +$4.15M ﹤0.01% 2478
2021
Q3 		– Sell
-14,170
Closed -$183K – 4523
2021
Q2 		$183K Sell
14,170
-38,030
-73% -$484K ﹤0.01% 4117
2021
Q1 		$678K Sell
52,200
-6,681
-11% -$96.9K ﹤0.01% 3532
2020
Q4 		$814K Buy
+58,881
New +$857K ﹤0.01% 3365
2018
Q1 		– Sell
-11,657
Closed -$52K – 4315
2017
Q4 		$52K Buy
+11,657
New +$64.7K ﹤0.01% 4204
2017
Q3 		– Sell
-81,950
Closed -$502K – 4267
2017
Q2 		$502K Buy
81,950
+931
+1% +$6.27K ﹤0.01% 3601
2017
Q1 		$595K Buy
+81,019
New +$374K ﹤0.01% 3485

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
NFG
Norris Financial Group Greenville, South Carolina $251M AUM 48.4% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Bank of New York Mellon's AUPH Position: Q2 2026 in Review

Bank of New York Mellon increased its Aurinia Pharmaceuticals (AUPH) stake by 4.5% in Q2 2026, buying an estimated $241K and bringing the position to 350,857 shares worth $5.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

Bank of New York Mellon first reported a position in AUPH in Q1 2017 and has held it in 23 quarters since. 138 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Bank of New York Mellon held 350,857 shares of Aurinia Pharmaceuticals worth $5.95M as of Q2 2026.
  • Bank of New York Mellon bought 15,082 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $241K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2340 holding.
  • Bank of New York Mellon first reported a position in Aurinia Pharmaceuticals in Q1 2017 and has held it in 23 quarters since.
  • 138 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.